Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SFT-009
- Development stage
- Preclinical
- Lead developer
- invoX Pharma
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
SFT-009 is an inhaled therapeutic candidate currently in early development by invoX Pharma. It is part of a pipeline of respiratory treatments that utilize the proprietary Softhaler® platform, a dry powder inhaler (DPI) technology designed for efficient and consistent drug delivery to the lungs. While the specific active pharmaceutical ingredient and its molecular target remain undisclosed, the candidate is being developed for an undisclosed indication within the scope of invoX's focus on pulmonary diseases such as COPD, asthma, and pulmonary fibrosis. As of early 2024, SFT-009 is positioned in the preclinical or early development stage.
Beyond the preview
Go deeper on SFT-009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SFT-009.